A Phase 3 study of Keytruda (pembrolizumab) in Asian patients with advanced hepatocellular carcinoma met is primary endpoint of overall survival, the developer Merck & Co Inc announced on 27 September. Patients in the trial had previously been treated with sorafenib, an approved treatment for kidney and liver cancers. Hepatocellular carcinoma is the most common type of primary liver cancer.
